Roche, Novartis underline U.S. plans after Trump pharma tariff announcement
By Paul Arnold ZURICH (Reuters) -Swiss companies Roche and Novartis on Friday flagged they did not expect to…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc](https://www.europesays.com/ch/wp-content/uploads/2026/07/1147849-380x220.png)
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2,…
Roche, Novartis underline U.S. plans after Trump pharma tariff announcement
By Paul Arnold ZURICH (Reuters) -Swiss companies Roche and Novartis on Friday flagged they did not expect to…
Roche, Novartis underline U.S. plans after Trump pharma tariff announcement
By Paul Arnold ZURICH (Reuters) -Swiss companies Roche and Novartis on Friday flagged they did not expect to…
Roche, Novartis underline U.S. plans after Trump pharma tariff announcement
By Paul Arnold ZURICH (Reuters) -Swiss companies Roche and Novartis on Friday flagged they did not expect to…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer](https://www.europesays.com/ch/wp-content/uploads/2026/03/964824-380x220.png)
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival,…